Increasing the efficacy of monoclonal antibodies

Dr Martina Zimmerman has used ThioFuc as part of the cell culture media in order to improve the potency of rituximab, which may in turn lead to a reduction in the number of antibody treatments required

The advent of monoclonal antibody (mAb) technology has allowed the production of antibodies that can target specific antigens on malignant tumour cells or other inflammatory molecules that are known to exacerbate diseases such as rheumatoid arthritis or Crohn’s disease. Dr Martina Zimmermann, Dr Aline Zimmer, and their team from Merck KGaA, Darmstadt, Germany, added 5-Thio-L-Fucose (ThioFuc) to the cell culture […]

Read More…

Could a serpin antibody help to treat type 1 diabetes?

Could a serpin antibody help to treat type 1 diabetes? Investigating the connection between inflammation and tissue regeneration.

Research from Dr Jan Czyzyk and his team at the University of Minnesota, USA, explores the balance between proteases and serpins, and how their activity can in turn affect the inflammation and tissue regeneration of pancreatic islet cells. Their findings show that antibodies can be used to change this serpin–protease balance, with interesting impacts. Excitingly, their research opens the possibility […]

Read More…

Controlling aggregation in monoclonal antibody therapeutics

Monoclonal antibodies (mAbs) have become the most important form of protein therapeutic and represent five of the top ten selling drugs by revenue worldwide. mAbs bind monospecifically to certain cells or proteins. The objective is that this treatment will stimulate the patient’s immune system to attack those cells. Despite the many advantages of antibodies as therapeutics, their development is complicated […]

Read More…

Thank you for expressing interest in joining our mailing list and community. Below you can select how you’d like us to interact with you and we’ll keep you updated with our latest content.

You can change your preferences or unsubscribe by clicking the unsubscribe link in the footer of any email you receive from us, or by contacting us at at any time and if you have any questions about how we handle your data, please review our privacy agreement.

Would you like to learn more about our services?

We use MailChimp as our marketing automation platform. By clicking below to submit this form, you acknowledge that the information you provide will be transferred to MailChimp for processing in accordance with their Privacy Policy and Terms.

Subscribe to our FREE PUBLICATION